Arcellx Inc (ACLX)
53.74
-2.32
(-4.15%)
USD |
NASDAQ |
Jun 25, 16:00
53.74
0.00 (0.00%)
After-Hours: 19:54
Arcellx Free Cash Flow (Quarterly): -38.34M for March 31, 2024
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -38.34M |
| December 31, 2023 | 52.96M |
| September 30, 2023 | -18.03M |
| June 30, 2023 | -29.84M |
| March 31, 2023 | 181.06M |
| December 31, 2022 | -28.80M |
| September 30, 2022 | -17.03M |
| Date | Value |
|---|---|
| June 30, 2022 | -22.70M |
| March 31, 2022 | -33.05M |
| December 31, 2021 | -26.30M |
| September 30, 2021 | -12.01M |
| June 30, 2021 | -11.14M |
| March 31, 2021 | -10.57M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-38.34M
Minimum
Mar 2024
181.06M
Maximum
Mar 2023
-1.061M
Average
-18.03M
Median
Sep 2023
Free Cash Flow (Quarterly) Benchmarks
| Gilead Sciences Inc | 2.114B |
| BridgeBio Pharma Inc | -221.03M |
| Eli Lilly and Co | 83.20M |
| AbbVie Inc | 3.847B |
| Blueprint Medicines Corp | -102.62M |